Heron Therapeutics Inc. (HRTX) Stock Rating Upgraded by Zacks Investment Research
Heron Therapeutics Inc. (NASDAQ:HRTX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday.
According to Zacks, “Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. “
A number of other equities analysts have also commented on the company. Leerink Swann reaffirmed a “buy” rating and issued a $33.00 price target on shares of Heron Therapeutics in a report on Sunday, October 2nd. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $41.00 price target on shares of Heron Therapeutics in a report on Wednesday, August 3rd. Lake Street Capital reaffirmed a “buy” rating and issued a $45.00 price target on shares of Heron Therapeutics in a report on Tuesday, September 6th. Jefferies Group cut their price target on Heron Therapeutics from $46.00 to $40.00 and set a “buy” rating for the company in a report on Monday, October 3rd. Finally, Brean Capital started coverage on Heron Therapeutics in a report on Tuesday, October 4th. They issued a “buy” rating and a $41.00 price target for the company. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $42.29.
Shares of Heron Therapeutics (NASDAQ:HRTX) opened at 15.70 on Tuesday. Heron Therapeutics has a 12 month low of $15.13 and a 12 month high of $31.32. The company’s 50-day moving average price is $18.23 and its 200-day moving average price is $18.89.
Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Monday, August 8th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($0.96) by $0.21. Analysts forecast that Heron Therapeutics will post ($4.39) earnings per share for the current year.
In related news, insider Robert Rosen sold 100,000 shares of the stock in a transaction on Wednesday, August 10th. The stock was sold at an average price of $23.30, for a total value of $2,330,000.00. Following the sale, the insider now owns 102,640 shares in the company, valued at $2,391,512. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 20.31% of the stock is owned by corporate insiders.
Several large investors have recently modified their holdings of the company. BlackRock Group LTD increased its stake in Heron Therapeutics by 9.0% in the second quarter. BlackRock Group LTD now owns 10,816 shares of the biotechnology company’s stock worth $195,000 after buying an additional 897 shares during the last quarter. Parametric Portfolio Associates LLC purchased a new stake in Heron Therapeutics during the second quarter worth $213,000. BlackRock Advisors LLC increased its stake in Heron Therapeutics by 13.3% in the second quarter. BlackRock Advisors LLC now owns 15,104 shares of the biotechnology company’s stock worth $273,000 after buying an additional 1,769 shares during the last quarter. State Board of Administration of Florida Retirement System increased its stake in Heron Therapeutics by 8.3% in the second quarter. State Board of Administration of Florida Retirement System now owns 16,739 shares of the biotechnology company’s stock worth $302,000 after buying an additional 1,283 shares during the last quarter. Finally, American International Group Inc. increased its stake in Heron Therapeutics by 8.1% in the second quarter. American International Group Inc. now owns 18,293 shares of the biotechnology company’s stock worth $330,000 after buying an additional 1,369 shares during the last quarter.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.